Author

Amy Woo

A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A NOVEL RECOMBINANT, HUMANISED, ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY (RPC4046) IN PATIENTS WITH ACTIVE EOSINOPHILIC OESOPHAGITIS: RESULTS OF THE HEROES STUDY

Ikuo Hirano, Margaret H. Collins, Yudith Assouline-Dayan, Larry Evans, Sandeep Gupta, Alain Schoepfer, Michael Grimm, Heather Smith, Cindy-ann Tompkins, Amy Woo, Robert Peach, Paul A. Frohna, Sheila Gujrathi, Richard Aranda, Evan S Dellon

EFFICACY OF RPC4046, AN ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS: ANALYSIS OF THE STEROID-REFRACTORY SUBGROUP FROM THE HEROES STUDY

Evan S Dellon, Margaret H. Collins, Yehudith Assouline Dayan, Larry Evans, Sandeep Gupta, Alain Schoepfer, Alex Straumann, Ekaterina Safroneeva, Amy Woo, Gregory J. Opiteck, Allan Olson, Richard Aranda, Marc E. Rothenberg, Ikuo Hirano

LONG-TERM EFFICACY AND SAFETY OF RPC4046, AN ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY, IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE OPEN-LABEL EXTENSION OF THE HEROES STUDY

Evan S Dellon, Margaret H. Collins, Yehudith Assouline Dayan, Larry Evans, Sandeep Gupta, Alain Schoepfer, Alex Straumann, Ekaterina Safroneeva, Amy Woo, Allan Olson, Gregory J. Opiteck, Richard Aranda, Ikuo Hirano

MARKERS OF ESOPHAGEAL EPITHELIAL-MESENCHYMAL TRANSITION ARE SIGNIFICANTLY REDUCED IN ACTIVE EOSINOPHILIC ESOPHAGITIS FOLLOWING 16 WEEKS OF TREATMENT WITH RPC4046, AN ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY

Peter Gann, Ryan Deaton, Nathan McMahon, Margaret H. Collins, Evan S Dellon, Ikuo Hirano, Michael Grimm, Amy Woo, Mahinda Karunaratne, Allan Olson, Richard Aranda, Gregory J. Opiteck

Item 1 - 4 / 4
1